This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Neovasc Management

Management criteria checks 2/4

Key information

Fred Colen

Chief executive officer

US$4.0m

Total compensation

CEO salary percentage	10.1%
CEO tenure	5.3yrs
CEO ownership	0.4%
Management average tenure	4.3yrs
Board average tenure	16.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Fred Colen's remuneration changed compared to Neovasc's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	-US$41m
Sep 30 2022	n/a	n/a	-US$34m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$4m	US$406k	-US$25m
Sep 30 2021	n/a	n/a	-US$23m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$3m	US$406k	-US$29m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$2m	US$402k	-US$35m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$20m
Mar 31 2019	n/a	n/a	-US$61m
Dec 31 2018	US$1m	US$390k	-US$108m

Compensation vs Market: Fred's total compensation ($USD4.03M) is above average for companies of similar size in the German market ($USD423.52K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.

CEO

Fred Colen (70 yo)

5.3yrs

Tenure

US$4,026,365

Compensation

Mr. Fredericus A. Colen, also known as Fred, has been President and Chief Executive Officer at Neovasc Inc. since January 22, 2018. Mr. Colen is Director at Neovasc Inc. since June 4, 2019. He serves as In...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fredericus Colen	President	5.3yrs	US$4.03m	0.43% $ 320.3k
Christopher Clark	CFO & Corporate Secretary	16yrs	US$1.85m	0.095% $ 71.2k
William Little	Chief Operating Officer	3.4yrs	US$1.98m	0.29% $ 215.7k
John Panton	Chief Quality Officer	2.9yrs	US$678.40k	0.045% $ 33.5k
Susan Milne	Vice President of Human Resources	no data	no data	no data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: G5Z's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fredericus Colen	President	3.8yrs	US$4.03m	0.43% $ 320.3k
Paul Geyer	Independent Director	22.4yrs	US$177.33k	0.67% $ 498.6k
Douglas Janzen	Independent Director	17.8yrs	US$167.33k	1.41% $ 1.1m
Alexei Marko	Independent Director	19.8yrs	US$167.33k	0.016% $ 12.4k
Steven Rubin	Independent Chairman of the Board	14.8yrs	US$177.33k	0.045% $ 33.6k
Norman Radow	Independent Director	3.6yrs	US$192.07k	0.10% $ 74.8k

16.3yrs

Average Tenure

60yo

Average Age

Experienced Board: G5Z's board of directors are seasoned and experienced ( 16.3 years average tenure).

This company listing is no longer active

Neovasc Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director recently bought €76k worth of stock

Neovasc Inc., Annual General Meeting, Apr 12, 2022

Chief Operating Officer recently bought €70k worth of stock

Recent updates

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

Neovasc Announces Progress on COSIRA-II Clinical Trial

Third quarter 2022 earnings released: US$3.00 loss per share (vs US$2.79 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Neovasc Inc. to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Neovasc Inc. Announces Positive Clinical Data at Transcatheter Cardiovascular Therapeutics Conference and Provides Update on Mitral Valve Program

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Independent Director recently bought €76k worth of stock

Second quarter 2022 earnings released: US$3.29 loss per share (vs US$3.35 loss in 2Q 2021)

Neovasc Inc. to Report Q2, 2022 Results on Aug 11, 2022

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2022 earnings released: US$3.75 loss per share (vs US$1.11 loss in 1Q 2021)

Neovasc Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Neovasc Inc. to Report Q4, 2021 Results on Mar 10, 2022

Neovasc Inc., Annual General Meeting, Apr 12, 2022

German Institute for the Hospital Remuneration System Awards Neovasc, Inc.'s Reducer™ NUB Status 1 Designation for 2022

Neovasc Inc. Announces the Publication of Cost-Effectiveness Studies Supporting the Use of the Neovasc Reducer

Neovasc Inc. Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Neovasc Inc. Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal

Neovasc Announces First Patient Enrollment in Cosira-II Trial

Chief Operating Officer recently bought €70k worth of stock

The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)

Independent Director recently bought €65k worth of stock

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)

Independent Director recently bought €73k worth of stock

Neovasc Inc Provides Corporate Update

Neovasc Reducer System Receives First National Reimbursement in Europe

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. Provides Update on German Litigation

Neovasc Announces First Patient Enrollment in COSIMA Trial

First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)

Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)

Revenue misses expectations

Neovasc Inc. to Report Q4, 2020 Results on Mar 11, 2021

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

New 90-day high: €1.25

American Medical Association Issues New CPT Code for Neovasc Reducer Procedure

New 90-day high: €1.10

Neovasc Inc. Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)

Zhang Investor Law Alerts Investors to Upcoming Deadline in Securities Class Action Lawsuit Against Neovasc Inc

Pomerantz LLP Announces A Class Action Lawsuit Filed Against Neovasc Inc. and Certain of Its Officers

Neovasc Announces First Neovasc Reducer Implants in France

Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $6.10681 million.

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

New 90-day low: €0.56

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Neovasc Inc

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

Pawar Law Group Announces A Securities Class Action Lawsuit Against Neovasc Inc

New 90-day low: €0.61

Third quarter 2020 earnings released: US$0.51 loss per share

Revenue beats expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Neovasc Inc

New 90-day low: €1.64

Neovasc, Inc. Treats 300 Patient in Germany with the Neovasc Reducer

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $12.581842 million.

New 90-day low - €1.90

Earnings released

Neovasc Inc. to Report Q2, 2020 Results on Aug 06, 2020

CEO Compensation Analysis

CEO

Tenure